Zhejiang Jolly PharmaceuticalLTD Past Earnings Performance
Past criteria checks 5/6
Zhejiang Jolly PharmaceuticalLTD has been growing earnings at an average annual rate of 45%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 20.4% per year. Zhejiang Jolly PharmaceuticalLTD's return on equity is 19.9%, and it has net margins of 20.5%.
Key information
45.0%
Earnings growth rate
42.3%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | 20.4% |
Return on equity | 19.9% |
Net Margin | 20.5% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Zhejiang Jolly PharmaceuticalLTD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 2,522 | 518 | 982 | 72 |
30 Jun 24 | 2,359 | 481 | 957 | 78 |
31 Mar 24 | 2,120 | 428 | 926 | 76 |
31 Dec 23 | 1,942 | 383 | 875 | 79 |
30 Sep 23 | 1,926 | 356 | 890 | 72 |
30 Jun 23 | 1,922 | 336 | 929 | 73 |
31 Mar 23 | 1,861 | 302 | 927 | 71 |
01 Jan 23 | 1,805 | 273 | 927 | 64 |
30 Sep 22 | 1,723 | 252 | 908 | 64 |
30 Jun 22 | 1,655 | 228 | 874 | 61 |
31 Mar 22 | 1,557 | 204 | 837 | 50 |
01 Jan 22 | 1,457 | 179 | 795 | 46 |
30 Sep 21 | 1,400 | 158 | 745 | 42 |
30 Jun 21 | 1,322 | 145 | 719 | 33 |
31 Mar 21 | 1,238 | 122 | 678 | 31 |
31 Dec 20 | 1,091 | 89 | 602 | 30 |
30 Sep 20 | 1,024 | 49 | 597 | 30 |
30 Jun 20 | 949 | 29 | 555 | 30 |
31 Mar 20 | 901 | 26 | 530 | 29 |
31 Dec 19 | 911 | 26 | 529 | 27 |
30 Sep 19 | 859 | 34 | 499 | 26 |
30 Jun 19 | 767 | 14 | 445 | 27 |
31 Mar 19 | 764 | 23 | 432 | 26 |
31 Dec 18 | 730 | 21 | 413 | 27 |
30 Sep 18 | 609 | 20 | 407 | 22 |
30 Jun 18 | 629 | 31 | 388 | 33 |
31 Mar 18 | 647 | 43 | 385 | 27 |
31 Dec 17 | 679 | 45 | 383 | 21 |
30 Sep 17 | 804 | 49 | 378 | 17 |
30 Jun 17 | 814 | 63 | 396 | 0 |
31 Mar 17 | 830 | 59 | 416 | 0 |
31 Dec 16 | 840 | 72 | 424 | 0 |
30 Sep 16 | 819 | 86 | 410 | 0 |
30 Jun 16 | 810 | 87 | 413 | 0 |
31 Mar 16 | 720 | 85 | 373 | 0 |
31 Dec 15 | 671 | 85 | 363 | 0 |
30 Sep 15 | 657 | 103 | 361 | 0 |
30 Jun 15 | 620 | 111 | 349 | 0 |
31 Mar 15 | 572 | 107 | 330 | 0 |
31 Dec 14 | 515 | 103 | 312 | 0 |
30 Sep 14 | 457 | 94 | 301 | 0 |
30 Jun 14 | 440 | 90 | 297 | 0 |
31 Mar 14 | 431 | 85 | 293 | 0 |
31 Dec 13 | 419 | 81 | 285 | 0 |
Quality Earnings: 300181 has high quality earnings.
Growing Profit Margin: 300181's current net profit margins (20.5%) are higher than last year (18.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300181's earnings have grown significantly by 45% per year over the past 5 years.
Accelerating Growth: 300181's earnings growth over the past year (45.4%) exceeds its 5-year average (45% per year).
Earnings vs Industry: 300181 earnings growth over the past year (45.4%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 300181's Return on Equity (19.9%) is considered low.